The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
Gilat's Management will discuss its fourth quarter and full year 2024 results and business achievements and participate in a question-and-answer session: 09:30 AM EST / 16:30 IST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback